Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis

References

• World Health Organisation. Asthma 2020 [cited 2021 Jun]. Available from: https://www.who.int/news-room/q-a-detail/asthma.
   Google Scholar
• Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62(9):758–766.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• CDC. Flu and People with Asthma 2020 [cited 2021 Jun]. Available from: https://www.cdc.gov/flu/highrisk/asthma.htm.
   Google Scholar
• Homaira N, Briggs N, Jl O, et al. Impact of influenza on hospitalization rates in children with a range of chronic lung diseases. Influenza Other Respir Viruses. 2019;13(3):233–239.
   PubMed Web of Science ®Google Scholar
• Miller EK, Griffin MR, Edwards KM, et al. Influenza burden for children with asthma. Pediatrics. 2008;121(1):1–8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccination Last reviewed 2020.  Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination.
   Google Scholar
• CDC. Healthy habits to prevent flu 2020 [cited 2021 Jun]. Available from: https://www.cdc.gov/flu/prevent/actions-prevent-flu.htm.
   Google Scholar
• Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020;69(8):1–24.
   PubMed Web of Science ®Google Scholar
• Young K, Gemmill I, Harrison R, Immunization NACo. Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021. Canada Communicable Disease Report. 2020;46(5):132–137.
   PubMedGoogle Scholar
• Public Health England. The national flu immunisation programme 2020 to 2021- update Last reviewed 2020. [cited 2021 Jun]. Available from: https://www.england.nhs.uk/wp-content/uploads/2020/05/Letter_AnnualFlu_2020-21_20200805.pdf.
   Google Scholar
• Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(8):1388–1395.
   PubMed Web of Science ®Google Scholar
• MedImmune LLC FLUMIST Quadrivalent. 2020-2021 formula. Highlights of Prescribing Information 2020. [cited 2021 Jun]. Available from: https://www.azpicentral.com/flumistquadrivalent/flumistquadrivalent.pdf.
   Google Scholar
• AstraZeneca. Fluenz Tetra Summary of Product Characteristics 2019.[cited 2021 Jun]. Available from: https://www.ema.europa.eu/en/documents/product-information/fluenz-tetra-epar-product-information_en.pdf.
   Google Scholar
• Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23(2):138–144.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685–696.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA FluMist full prescribing information 2020. [cited 2021 Jun]. Available from: https://www.fda.gov/media/120689/download.
   Google Scholar
• Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25(10):860–869.
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10):870–879.
   PubMed Web of Science ®Google Scholar
• Redding G, Re W, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21(1):44–48.
   PubMed Web of Science ®Google Scholar
• Tennis P, Toback SL, Andrews EB, et al. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009–2010 season. Vaccine. 2012;30(42):6099–6102.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Fleming L, Saglani S, et al. Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma. J Allergy Clin Immunol. 2020;145(4):1157–64 e6.
   PubMed Web of Science ®Google Scholar
• Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008;27(5):444–452.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Dubovsky F, Yi T, et al. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis. 2012;31(10):2549–2557.
   PubMed Web of Science ®Google Scholar
• Tennis P, Toback SL, Andrews E, et al. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine. 2011;29(31):4947–4952.
   PubMed Web of Science ®Google Scholar
• Ray GT, Lewis N, Goddard K, et al. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017;35(20):2668–2675.
   PubMed Web of Science ®Google Scholar
• Nordin JD, Vazquez-Benitez G, Olsen A, et al. Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma. Vaccine. 2019;37(30):4055–4060.
   PubMed Web of Science ®Google Scholar
• Baxter R, Eaton A, Hansen J, et al. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49 years. Vaccine. 2017;35(9):1254–1258.
   PubMed Web of Science ®Google Scholar
• Caspard H, Steffey A, Mallory RM, et al. Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink. BMJ Open. 2018;8(12):e023118.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116(3):e397–407.
   PubMed Web of Science ®Google Scholar
• Duffy J, Lewis M, Harrington T, et al. Live attenuated influenza vaccine use and safety in children and adults with asthma. Ann Allergy Asthma Immunol. 2017;118(4):439–444.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015;136(2):376–381.
   PubMed Web of Science ®Google Scholar
• Herve C, Laupeze B, Del Giudice G, et al. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4(1):39.
   PubMed Web of Science ®Google Scholar
• Public Health England. Influenza: the green book, chapter 19 Last reviewed 2018.[cited 2021 Jun]. Available from: https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19.
   Google Scholar